Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Glaukos Co. stock logo
GKOS
Glaukos
$102.43
+6.0%
$141.84
$84.08
$163.71
$5.79B0.99577,864 shs1.09 million shs
Penumbra, Inc. stock logo
PEN
Penumbra
$273.51
+4.9%
$269.89
$148.00
$310.00
$10.53B0.51397,509 shs307,493 shs
Smith & Nephew plc stock logo
SNN
Smith & Nephew
$28.59
+1.3%
$26.35
$23.65
$31.72
$12.50B0.83818,020 shs774,619 shs
Solventum Co. stock logo
SOLV
Solventum
$74.31
+2.8%
$74.52
$47.16
$85.92
$12.85BN/A1.43 million shs1.14 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Glaukos Co. stock logo
GKOS
Glaukos
+5.94%-1.64%-28.77%-26.27%+16.85%
Penumbra, Inc. stock logo
PEN
Penumbra
+4.90%-0.56%+2.28%+11.39%+17.21%
Smith & Nephew plc stock logo
SNN
Smith & Nephew
+1.29%-4.28%+12.68%+11.97%+2.75%
Solventum Co. stock logo
SOLV
Solventum
+2.59%-4.68%+0.94%+6.83%+7,430,999,900.00%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Glaukos Co. stock logo
GKOS
Glaukos
4.4896 of 5 stars
4.51.00.04.43.32.50.6
Penumbra, Inc. stock logo
PEN
Penumbra
4.4211 of 5 stars
2.45.00.03.73.02.51.9
Smith & Nephew plc stock logo
SNN
Smith & Nephew
2.2665 of 5 stars
1.03.02.50.02.90.03.1
Solventum Co. stock logo
SOLV
Solventum
1.0451 of 5 stars
2.02.00.00.03.40.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Glaukos Co. stock logo
GKOS
Glaukos
2.92
Moderate Buy$163.2559.38% Upside
Penumbra, Inc. stock logo
PEN
Penumbra
2.88
Moderate Buy$294.477.66% Upside
Smith & Nephew plc stock logo
SNN
Smith & Nephew
2.00
Hold$27.00-5.55% Downside
Solventum Co. stock logo
SOLV
Solventum
2.00
Hold$79.867.46% Upside

Current Analyst Ratings Breakdown

Latest GKOS, SOLV, SNN, and PEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/14/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$320.00
3/12/2025
Smith & Nephew plc stock logo
SNN
Smith & Nephew
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
3/5/2025
Solventum Co. stock logo
SOLV
Solventum
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$73.00 ➝ $80.00
3/3/2025
Solventum Co. stock logo
SOLV
Solventum
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$70.00 ➝ $82.00
3/3/2025
Solventum Co. stock logo
SOLV
Solventum
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSell ➝ Sell$63.00 ➝ $71.00
2/28/2025
Solventum Co. stock logo
SOLV
Solventum
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$73.00 ➝ $75.00
2/28/2025
Solventum Co. stock logo
SOLV
Solventum
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$75.00 ➝ $84.00
2/26/2025
Smith & Nephew plc stock logo
SNN
Smith & Nephew
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold$27.00 ➝ $27.00
2/26/2025
Solventum Co. stock logo
SOLV
Solventum
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$80.00 ➝ $85.00
2/21/2025
Glaukos Co. stock logo
GKOS
Glaukos
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$153.00 ➝ $160.00
2/21/2025
Glaukos Co. stock logo
GKOS
Glaukos
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$149.00 ➝ $176.00
(Data available from 3/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Glaukos Co. stock logo
GKOS
Glaukos
$383.48M15.11N/AN/A$9.46 per share10.83
Penumbra, Inc. stock logo
PEN
Penumbra
$1.19B8.82$2.60 per share105.01$29.88 per share9.15
Smith & Nephew plc stock logo
SNN
Smith & Nephew
$5.81B2.15$3.57 per share8.00$11.94 per share2.39
Solventum Co. stock logo
SOLV
Solventum
$8.25B1.56N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Glaukos Co. stock logo
GKOS
Glaukos
-$134.66M-$2.87N/AN/AN/A-39.04%-16.53%-10.61%5/7/2025 (Estimated)
Penumbra, Inc. stock logo
PEN
Penumbra
$90.95M$0.34804.4554.592.831.17%9.74%7.35%5/6/2025 (Estimated)
Smith & Nephew plc stock logo
SNN
Smith & Nephew
$263M$2.1613.2314.291.26N/AN/AN/AN/A
Solventum Co. stock logo
SOLV
Solventum
N/A$2.7527.0213.541.94N/AN/AN/A5/8/2025 (Estimated)

Latest GKOS, SOLV, SNN, and PEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/20/2025Q4 2024
Glaukos Co. stock logo
GKOS
Glaukos
-$0.38-$0.40-$0.02-$0.60$100.72 million$105.50 million
2/18/2025Q4 2024
Penumbra, Inc. stock logo
PEN
Penumbra
$0.88$0.97+$0.09$0.86$311.63 million$315.52 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Glaukos Co. stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A
Smith & Nephew plc stock logo
SNN
Smith & Nephew
$0.893.11%N/A41.20%N/A
Solventum Co. stock logo
SOLV
Solventum
N/AN/AN/AN/AN/A

Latest GKOS, SOLV, SNN, and PEN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/26/2025
Smith & Nephew plc stock logo
SNN
Smith & Nephew
semi-annual$0.44702.5%3/28/20253/28/20255/28/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Glaukos Co. stock logo
GKOS
Glaukos
0.19
5.54
4.71
Penumbra, Inc. stock logo
PEN
Penumbra
0.02
6.01
3.25
Smith & Nephew plc stock logo
SNN
Smith & Nephew
0.63
2.51
1.11
Solventum Co. stock logo
SOLV
Solventum
2.45
1.15
0.83

Institutional Ownership

CompanyInstitutional Ownership
Glaukos Co. stock logo
GKOS
Glaukos
99.04%
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%
Smith & Nephew plc stock logo
SNN
Smith & Nephew
25.64%
Solventum Co. stock logo
SOLV
Solventum
N/A

Insider Ownership

CompanyInsider Ownership
Glaukos Co. stock logo
GKOS
Glaukos
6.40%
Penumbra, Inc. stock logo
PEN
Penumbra
5.00%
Smith & Nephew plc stock logo
SNN
Smith & Nephew
1.00%
Solventum Co. stock logo
SOLV
Solventum
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Glaukos Co. stock logo
GKOS
Glaukos
78056.57 million51.61 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
4,20038.52 million36.59 millionOptionable
Smith & Nephew plc stock logo
SNN
Smith & Nephew
18,452437.20 million432.83 millionOptionable
Solventum Co. stock logo
SOLV
Solventum
22,000172.99 millionN/AOptionable

Recent News About These Companies

Solventum (SOLV) and The Competition Head-To-Head Contrast
Critical Survey: Solventum (SOLV) and Its Competitors
Solventum Corp. stock falls Thursday, underperforms market
Solventum Co. stock logo
Solventum Co. (NYSE:SOLV) Shares Sold by Amundi
Solventum (SOLV) and Its Peers Head to Head Review
Solventum (SOLV) and Its Competitors Head to Head Contrast

New MarketBeat Followers Over Time

Media Sentiment Over Time

Glaukos stock logo

Glaukos NYSE:GKOS

$102.43 +5.83 (+6.04%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$101.02 -1.42 (-1.38%)
As of 03/14/2025 06:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Penumbra stock logo

Penumbra NYSE:PEN

$273.51 +12.88 (+4.94%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$274.29 +0.78 (+0.28%)
As of 03/14/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Smith & Nephew stock logo

Smith & Nephew NYSE:SNN

$28.59 +0.38 (+1.33%)
Closing price 03/14/2025 03:58 PM Eastern
Extended Trading
$28.57 -0.02 (-0.06%)
As of 03/14/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

Solventum stock logo

Solventum NYSE:SOLV

$74.31 +2.01 (+2.78%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$73.39 -0.92 (-1.23%)
As of 03/14/2025 06:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.